Web of Science: 5 citations, Scopus: 4 citations, Google Scholar: citations,
Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis
Fernández de Retana Alda, Sofía (Vall d'Hebron Institut de Recerca)
Cano Sarabia, Antonia María (Institut Català de Nanociència i Nanotecnologia)
Marazuela, Paula (Hospital Universitari Vall d'Hebron)
Sánchez Quesada, José Luis (Hospital de la Santa Creu i Sant Pau)
García León, Annabel (Institut d'Investigacions Biomèdiques Sant Pau)
Montañola, Alex (Vall d'Hebron Institut de Recerca)
Montaner, Joan (Vall d'Hebron Institut de Recerca)
Maspoch Comamala, Daniel (Institut Català de Nanociència i Nanotecnologia)
Hernández Guillamón, María del Mar (Vall d'Hebron Institut de Recerca)

Date: 2017
Abstract: Cerebral β-amyloidosis is a major feature of Alzheimer's disease (AD), characterized by the accumulation of β-amyloid protein (Aβ) in the brain. Several studies have implicated lipid/lipoprotein metabolism in the regulation of β-amyloidosis. In this regard, HDL (High Density Lipoprotein)-based therapies could ameliorate pathological features associated with AD. As apolipoprotein J (ApoJ) is a natural chaperone that interacts with Aβ, avoiding its aggregation and toxicity, in this study we propose to prepare reconstituted rHDL-rApoJ nanoparticles by assembling phospholipids with recombinant human ApoJ (rApoJ). Hence, rHDL particles were prepared using the cholate dialysis method and characterized by N-PAGE, dynamic light scattering, circular dichroism and electron transmission microscopy. The preparation of rHDL particles showed two-sized populations with discoidal shape. Functionally, rHDL-rApoJ maintained the ability to prevent the Aβ fibrillization and mediated a higher cholesterol efflux from cultured macrophages. Fluorescently-labelled rHDL-rApoJ nanoparticles were intravenously administrated in mice and their distribution over time was determined using an IVIS Xenogen® imager. It was confirmed that rHDL-rApoJ accumulated in the cranial region, especially in old transgenic mice presenting a high cerebral Aβ load. In conclusion, we have standardized a reproducible protocol to produce rHDL-rApoJ nanoparticles, which may be potentially considered as a therapeutic option for β-amyloid-related pathologies.
Note: Altres ajuts: Fundació La Marató de TV3 [40/U/2014]
Note: Número d'acord de subvenció ISCIII/PI14/01134
Note: Número d'acord de subvenció ISCIII/PI13/00364
Note: Número d'acord de subvenció ISCIII/RD16/0019/0021
Note: Número d'acord de subvenció ISCIII/CP12/03259
Note: Número d'acord de subvenció MINECO/SEV-2013-0295
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès.
Document: article ; recerca ; publishedVersion
Subject: Diseases of the nervous system ; Nanomedicine
Published in: Scientific reports, Vol. 7 (November 2017) , art. 14637, ISSN 2045-2322

DOI: 10.1038/s41598-017-15215-w
PMID: 29116115


13 p, 3.3 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (scientific output) > Health sciences and biosciences > Institut d'Investigació Biomèdica Sant Pau
Research literature > UAB research groups literature > Research Centres and Groups (scientific output) > Experimental sciences > Catalan Institute of Nanoscience and Nanotechnology (ICN2)
Articles > Research articles
Articles > Published articles

 Record created 2019-06-03, last modified 2019-11-06



   Favorit i Compartir